Deliberate on your choices thoughtfully and invest in methods that promote your overall wellness
Clinical translational research shows that in a Phase II clinical trial of newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) (n=100), oral HDAC inhibitor Tucidinostat (20 mg per dose) in combination with the R-CHOP regimen achieved an 86% complete response rate (91)
Expert-Led Care: Licensed medical providers guide your treatment
for long-term storage keep it frozen, away from light and moisture
For more information on your Medicare coverage, please be sure to seek legal, medical, pharmaceutical, or financial advice from a licensed professional or telephone Century Medicare at (847)577-8574
GHK-CU $49.99 In stock Description GHK-Cu is a naturally occurring copper peptide complex composed of glycyl-L-histidyl-L-lysine bound to copper(II)